Targeting Protein Kinase G to Treat Cardiac Proteotoxicity

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Proteostasis

Background:

• Impaired protein kinase G (PKG) signaling and protein quality control (PQC) are key features of cardiac diseases, including heart failure.
• Dysregulation of PKG and PQC contributes to cardiac hypertrophy, remodeling, and reduced cell survival.
• While PKG activation therapies are available, safe methods to enhance cardiomyocyte PQC are lacking due to limited knowledge of regulatory proteins.

Purpose of the Study:

• To review the roles of PKG and PQC in cardiac disease pathogenesis.
• To summarize evidence supporting PKG stimulation for improving cardiomyocyte PQC.
• To highlight the therapeutic potential of targeting cardiac proteotoxicity via PKG.

Main Methods:

• Review of experimental and clinical data.
• Analysis of studies investigating PKG's role in cardiac PQC.
• Examination of FDA-approved therapies for PKG activation.

Main Results:

• PKG signaling is recently shown to regulate cardiac PQC in both physiological and pathological conditions.
• Pharmacological activation of PKG using existing FDA-approved drugs enhances cardiomyocyte PQC.
• PKG activation alleviates cardiac disease in pre-clinical models.

Conclusions:

• PKG plays a critical role in maintaining cardiac PQC.
• Stimulating PKG offers a potential therapeutic strategy to combat cardiac proteotoxicity and disease.
• Further research into PKG-regulated PQC could lead to novel treatments for heart failure.